Table 1.
OR51E1 | OR1A1 | OR2W1 | MOR256–3 | |
---|---|---|---|---|
in vitro/SVM | 2/4 | 7/18 | 2/5 | 5/10 |
hit rate | 50% | 39% | 40% | 50% |
Numbers of in-vitro-validated and SVM-predicted agonists and corresponding hit rate for the four systems studied.
OR51E1 | OR1A1 | OR2W1 | MOR256–3 | |
---|---|---|---|---|
in vitro/SVM | 2/4 | 7/18 | 2/5 | 5/10 |
hit rate | 50% | 39% | 40% | 50% |
Numbers of in-vitro-validated and SVM-predicted agonists and corresponding hit rate for the four systems studied.